Thursday, March 03, 2022 10:26:15 AM
Here is what Deitsch the CEO has done for NPHC in 19 years:
Added Many patents and trademarks to Nutra's portfolio
Clinical Trials in Multiple Phases
1. Multiple Sclerosis Trials
2. Herpes Simplex Infections 1 & 2 Trials
3. Adrenomyeloneuropathy Trials
4. HIV Trials
5. Amyotrophic Lateral Sclerosis Trials
6. Rheumatoid Arthritis Trials
7. Pain Trials
Products launched and brought to Market
1. Cobroxin
2. Nyloxin
3. Pet Pain Away
4. Equine pain Away
5. Luxury Feet
Published Research
http://receptopharm.com/drug_development/published_research.php
https://www.nutrapharma.com/research
Increased Sales on Amazon and Walmart
RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis
Huge personal loans from Deitsch to NPHC tells me the CEO knows and believes in NPHC
Nyloxin, I put that Sh*t on everything!!!
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM